Suppr超能文献

阿托伐他汀引起的血清碱性磷酸酶异常显著升高。

An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase.

作者信息

Chapman George, Tanner Stephanie

机构信息

Medicine for Older People - Community Assessment and Treatment Service, Buckinghamshire Healthcare NHS Trust, Aylesbury, UK

Medicine for Older People - Community Assessment and Treatment Service, Buckinghamshire Healthcare NHS Trust, Aylesbury, UK.

出版信息

BMJ Case Rep. 2020 Feb 10;13(2):e231839. doi: 10.1136/bcr-2019-231839.

Abstract

A 90-year-old woman is referred six months after a transient ischaemic attack (TIA) with asymptomatic cholestatic liver function test (LFT) derangement. Following the TIA, atorvastatin and clopidogrel therapy are initiated. This is added to pre-existent once daily nifedipine for hypertension. Nifedipine (a weak inhibitor of CYP3A4 and competing substrate) and clopidogrel (a competitive inhibitor of CYP3A4) may have affected the metabolism of atorvastatin, resulting in the elevation of serum alkaline phosphatase levels to over six times the upper limit of normal. More often, statin therapy elevates serum alanine aminotransferase levels. Drug-induced liver injury (DILI) was deemed 'probable' as judged by the Roussel Uclaf Causality Assessment Method score. Statin therapy remains overwhelmingly safe, with benefits outweighing risks in the vast majority. The UK recommended LFT monitoring regime facilitates early recognition of DILI. Case reports are examined where similar drug combinations resulted in severe morbidity and mortality.

摘要

一名90岁女性在短暂性脑缺血发作(TIA)六个月后前来就诊,伴有无症状性胆汁淤积性肝功能试验(LFT)紊乱。TIA发作后,开始使用阿托伐他汀和氯吡格雷治疗。这两种药物加用了之前每日服用一次的硝苯地平用于治疗高血压。硝苯地平(一种CYP3A4的弱抑制剂和竞争性底物)和氯吡格雷(一种CYP3A4的竞争性抑制剂)可能影响了阿托伐他汀的代谢,导致血清碱性磷酸酶水平升高至正常上限的六倍以上。更常见的是,他汀类药物治疗会使血清丙氨酸氨基转移酶水平升高。根据乌法因果关系评估法评分,药物性肝损伤(DILI)被判定为“很可能”。他汀类药物治疗总体上仍然非常安全,在绝大多数情况下益处大于风险。英国推荐的LFT监测方案有助于早期识别DILI。对一些病例报告进行了研究,其中类似的药物组合导致了严重的发病和死亡。

相似文献

1
An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase.
BMJ Case Rep. 2020 Feb 10;13(2):e231839. doi: 10.1136/bcr-2019-231839.
3
Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1169-1187. doi: 10.1080/17425255.2018.1539077. Epub 2018 Oct 29.
4
Republished: An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase.
Drug Ther Bull. 2021 Mar;59(3):43-47. doi: 10.1136/dtb.2020.231839rep. Epub 2020 Oct 22.
5
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.
J Hepatol. 2012 Feb;56(2):374-80. doi: 10.1016/j.jhep.2011.07.023. Epub 2011 Sep 1.
6
Drug-induced liver injury in the Australian setting.
J Clin Pharm Ther. 2013 Apr;38(2):115-20. doi: 10.1111/jcpt.12039. Epub 2013 Jan 27.
7
Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin.
Intern Med. 2019 Sep 15;58(18):2663-2667. doi: 10.2169/internalmedicine.2708-19. Epub 2019 Jun 7.
9
Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.
Gastroenterology. 2013 Jun;144(7):1419-25, 1425.e1-3; quiz e19-20. doi: 10.1053/j.gastro.2013.02.006. Epub 2013 Feb 16.
10
Presentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt.
Sci Rep. 2020 Mar 20;10(1):5124. doi: 10.1038/s41598-020-61872-9.

本文引用的文献

1
Severe Rhabdomyolysis due to Presumed Drug Interactions between Atorvastatin with Amlodipine and Ticagrelor.
Case Rep Crit Care. 2017;2017:3801819. doi: 10.1155/2017/3801819. Epub 2017 May 25.
2
Investigation of liver dysfunction: who should we test for hepatitis E?
Eur J Gastroenterol Hepatol. 2017 Feb;29(2):215-220. doi: 10.1097/MEG.0000000000000781.
3
High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort.
PLoS One. 2016 Mar 16;11(3):e0151587. doi: 10.1371/journal.pone.0151587. eCollection 2016.
4
Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin.
J Am Pharm Assoc (2003). 2015 May-Jun;55(3):320-3. doi: 10.1331/JAPhA.2015.14151.
5
A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting.
Clin Interv Aging. 2014 Dec 1;9:2079-86. doi: 10.2147/CIA.S71178. eCollection 2014.
6
Statin-induced rhabdomyolysis: a comprehensive review of case reports.
Physiother Can. 2014 Spring;66(2):124-32. doi: 10.3138/ptc.2012-65.
7
An assessment by the Statin Liver Safety Task Force: 2014 update.
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S47-57. doi: 10.1016/j.jacl.2014.02.011.
8
Drug interactions with statins.
Acta Pharm. 2013 Sep;63(3):277-93. doi: 10.2478/acph-2013-0022.
9
Rhabdomyolysis induced acute renal failure secondary to statins.
Indian J Nephrol. 2013 May;23(3):211-3. doi: 10.4103/0971-4065.111853.
10
Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences.
Cardiovasc Ther. 2013 Dec;31(6):344-51. doi: 10.1111/1755-5922.12028.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验